# EDGAR Filing Document

**Accession Number:** 0001761055
**File Stem:** 0001410368-25-043451
**Filing Date:** 2025-12
**Character Count:** 68073
**Document Hash:** e992472d438d28da4e9432cc1bf121bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-25-043451.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001410368-25-043451

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251031

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock ETF Trust
- **CENTRAL INDEX KEY:** 0001761055

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23402
- **FILM NUMBER:** 251606866

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 8004417762

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

| Class ID   | Class Name                           | Ticker Symbol   |
|:---|:---|:---|
| C000221226 | iShares Health Innovation Active ETF |  |

## Nport-Ex

October 31, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

2025 Quarterly Report <br>&nbsp;&nbsp;&nbsp;&nbsp;(Unaudited)<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| **BlackRock ETF Trust** |
| • iShares Health Innovation Active ETF \| BMED \| NYSE Arca |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Not FDIC Insured • May Lose Value • No Bank Guarantee**<br>

------

Schedule of Investments (unaudited)

October 31, 2025

**iShares Health Innovation Active ETF**

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 33.7%** | **Biotechnology — 33.7%** | **Biotechnology — 33.7%** |
| 4D Molecular Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 295 | $3393 |
| AbbVie Inc. | &nbsp;&nbsp;&nbsp; 443 | 96592 |
| Akeso Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1000 | 14561 |
| Alkermes PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 870 | 26709 |
| Allogene Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1965 | 2437 |
| Alnylam Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 115 | 52445 |
| Amgen Inc. | &nbsp;&nbsp;&nbsp; 305 | 91021 |
| Apogee Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 155 | 8771 |
| Arcellx Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 351 | 31678 |
| Arcus Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1130 | 22284 |
| Ascendis Pharma A/S, ADR<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 58 | 11693 |
| Autolus Therapeutics PLC , ADR<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 2035 | 3154 |
| Avalo Therapeutics Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 170 | 3065 |
| Avidity Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 87 | 6077 |
| Beam Therapeutics Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 507 | 12680 |
| BeOne Medicines Ltd., ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 101 | 31358 |
| Bicycle Therapeutics PLC, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 245 | 1977 |
| Biogen Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 775 | 119559 |
| Biohaven Ltd.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 206 | 3543 |
| BioMarin Pharmaceutical Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 212 | 11357 |
| BioNTech SE, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 77 | 8001 |
| Bridgebio Pharma Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 920 | 57629 |
| Cytokinetics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 220 | 13990 |
| Denali Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 910 | 14815 |
| Disc Medicine Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 131 | 11295 |
| Dyne Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 550 | 12419 |
| Enanta Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 445 | 4877 |
| Exact Sciences Corp.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 1786 | 115536 |
| Exelixis Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1426 | 55143 |
| Genmab A/S<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 363 | 103538 |
| Gilead Sciences Inc. | &nbsp;&nbsp;&nbsp; 766 | 91759 |
| Halozyme Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 425 | 27706 |
| Incyte Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 212 | 19818 |
| Insmed Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 555 | 105228 |
| Ionis Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1007 | 74820 |
| Kiniksa Pharmaceuticals International PLC, Class A<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 431 | 15951 |
| Kodiak Sciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 150 | 2719 |
| Merus NV<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 266 | 25233 |
| Moderna Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2686 | 72952 |
| Natera Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 560 | 111401 |
| Neurocrine Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 631 | 90366 |
| Nuvalent Inc., Class A<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 351 | 34861 |
| Olema Pharmaceuticals Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 306 | 2745 |
| ORIC Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 652 | 8580 |
| Oruka Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 315 | 8874 |
| Protagonist Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 466 | 36637 |
| PTC Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 435 | 29715 |
| REGENXBIO Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 510 | 6513 |
| Revolution Medicines Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 317 | 18652 |
| Rhythm Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 756 | 86003 |
| Scholar Rock Holding Corp.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 210 | 6220 |
| Stoke Therapeutics Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 1051 | 31572 |
| Summit Therapeutics Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 250 | 4727 |
| TScan Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2792 | 5416 |
| Upstream Bio Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 293 | 7574 |
| Vigil Neuroscience Inc., NVS<sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 484 | 24 |
| Viking Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 116 | 4417 |
| Vir Biotechnology Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 566 | 3373 |
| Vor BioPharma Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 305 | 7354 |
| Voyager Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 975 | 4553 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** | **Biotechnology (continued)** |
| Zealand Pharma A/S<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 312 | $24702 |
|  |  | 1922062 |
| **Health Care Equipment & Supplies — 19.6%** | **Health Care Equipment & Supplies — 19.6%** | **Health Care Equipment & Supplies — 19.6%** |
| Abbott Laboratories | &nbsp;&nbsp;&nbsp; 1516 | 187407 |
| Boston Scientific Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 907 | 91353 |
| Contra Abiomed Inc.<sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 246 | 569 |
| Dexcom Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 973 | 56648 |
| Edwards Lifesciences Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1880 | 155006 |
| EssilorLuxottica SA | &nbsp;&nbsp;&nbsp; 85 | 31129 |
| Hologic Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 922 | 68145 |
| Inspire Medical Systems Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 66 | 4757 |
| Insulet Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 407 | 127395 |
| Intuitive Surgical Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 162 | 86553 |
| Lantheus Holdings Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 306 | 17653 |
| Medtronic PLC | &nbsp;&nbsp;&nbsp; 1995 | 180947 |
| Novocure Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1340 | 17165 |
| Nyxoah SA, Class B<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 757 | 3929 |
| Penumbra Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 130 | 29558 |
| Sonova Holding AG, Registered | &nbsp;&nbsp;&nbsp; 105 | 28641 |
| Stryker Corp. | &nbsp;&nbsp;&nbsp; 77 | 27431 |
|  |  | 1114286 |
| **Health Care Providers & Services — 4.3%** | **Health Care Providers & Services — 4.3%** | **Health Care Providers & Services — 4.3%** |
| Cencora Inc. | &nbsp;&nbsp;&nbsp; 157 | 53036 |
| Guardant Health Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1495 | 139065 |
| McKesson Corp. | &nbsp;&nbsp;&nbsp; 66 | 53549 |
|  |  | 245650 |
| **Health Care Technology — 0.0%** | **Health Care Technology — 0.0%** | **Health Care Technology — 0.0%** |
| HeartFlow Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 21 | 780 |
| **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** |
| Frequency Therapeutics Inc., NVS<sup>(a)(d)</sup> | &nbsp;&nbsp;&nbsp; 420 |  |
| **Life Sciences Tools & Services — 22.1%** | **Life Sciences Tools & Services — 22.1%** | **Life Sciences Tools & Services — 22.1%** |
| Agilent Technologies Inc. | &nbsp;&nbsp;&nbsp; 841 | 123089 |
| Bio-Rad Laboratories Inc., Class A<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 156 | 49850 |
| Bio-Techne Corp. | &nbsp;&nbsp;&nbsp; 1142 | 71455 |
| Bruker Corp. | &nbsp;&nbsp;&nbsp; 437 | 17017 |
| Charles River Laboratories International Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 412 | 74189 |
| Danaher Corp. | &nbsp;&nbsp;&nbsp; 406 | 87444 |
| ICON PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 112 | 19244 |
| Illumina Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 787 | 97226 |
| IQVIA Holdings Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 600 | 129876 |
| Lonza Group AG, Registered | &nbsp;&nbsp;&nbsp; 220 | 151917 |
| Qiagen NV | &nbsp;&nbsp;&nbsp; 1102 | 51628 |
| Repligen Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 650 | 96889 |
| Samsung Biologics Co. Ltd.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 31 | 26503 |
| Tempus AI Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 525 | 47171 |
| Thermo Fisher Scientific Inc. | &nbsp;&nbsp;&nbsp; 208 | 118017 |
| West Pharmaceutical Services Inc. | &nbsp;&nbsp;&nbsp; 226 | 63748 |
| Wuxi Biologics Cayman Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 7500 | 34981 |
|  |  | 1260244 |
| **Pharmaceuticals — 17.0%** | **Pharmaceuticals — 17.0%** | **Pharmaceuticals — 17.0%** |
| Arvinas Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 650 | 6591 |
| AstraZeneca PLC | &nbsp;&nbsp;&nbsp; 325 | 26780 |
| Axsome Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 281 | 37932 |
| Bristol-Myers Squibb Co. | &nbsp;&nbsp;&nbsp; 1713 | 78918 |
| Contra Blueprint Medic, NVS<sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 110 | 107 |
| Contra Mirati Therapeutics Inc., NVS<sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 334 | 260 |
| Daiichi Sankyo Co. Ltd. | &nbsp;&nbsp;&nbsp; 600 | 14333 |
| Edgewise Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 586 | 10712 |
| Eisai Co. Ltd. | &nbsp;&nbsp;&nbsp; 2100 | 62371 |
| Elanco Animal Health Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 1425 | 31564 |

---

------

Schedule of Investments (unaudited)(continued)

October 31, 2025

**iShares Health Innovation Active ETF**

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Pharmaceuticals (continued)** | **Pharmaceuticals (continued)** | **Pharmaceuticals (continued)** |
| EyePoint Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 475 | $6218 |
| Galderma Group AG | &nbsp;&nbsp;&nbsp; 198 | 36771 |
| Harmony Biosciences Holdings Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 362 | 10342 |
| Johnson & Johnson | &nbsp;&nbsp;&nbsp; 976 | 184337 |
| LB Pharmaceuticals Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 1113 | 17953 |
| MBX Biosciences Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 870 | 19105 |
| Merck & Co. Inc. | &nbsp;&nbsp;&nbsp; 600 | 51588 |
| Novartis AG, Registered | &nbsp;&nbsp;&nbsp; 425 | 52599 |
| Nuvation Bio Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 1918 | 10012 |
| Ocular Therapeutix Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 485 | 5655 |
| Pfizer Inc. | &nbsp;&nbsp;&nbsp; 2192 | 54033 |
| Roche Holding AG, NVS | &nbsp;&nbsp;&nbsp; 297 | 96204 |
| Teva Pharmaceutical Industries Ltd., ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1437 | 29430 |
| UCB SA | &nbsp;&nbsp;&nbsp; 420 | 107999 |
| Ventyx Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1445 | 12326 |
| WaVe Life Sciences Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 466 | 4213 |
|  |  | 968353 |
| **Total Common Stocks — 96.7%** <br>**(Cost: $4,823,621)** | **Total Common Stocks — 96.7%** <br>**(Cost: $4,823,621)** | 5511375 |
| **Preferred Stocks** | **Preferred Stocks** | **Preferred Stocks** |
| **Life Sciences Tools & Services — 1.6%** | **Life Sciences Tools & Services — 1.6%** | **Life Sciences Tools & Services — 1.6%** |
| Sartorius AG, Preference Shares, NVS | &nbsp;&nbsp;&nbsp; 322 | 88591 |
| **Total Preferred Stocks — 1.6%** <br>**(Cost: $92,821)** | **Total Preferred Stocks — 1.6%** <br>**(Cost: $92,821)** | 88591 |
| **Total Long-Term Investments — 98.3%** <br>**(Cost: $4,916,442)** | **Total Long-Term Investments — 98.3%** <br>**(Cost: $4,916,442)** | 5599966 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 7.3%** | **Money Market Funds — 7.3%** | **Money Market Funds — 7.3%** |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency Shares, <br> 4.27%<sup>(e)(f)(g)</sup><br>| &nbsp;&nbsp;&nbsp; 346292 | $346465 |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency Shares, <br> 4.05%<sup>(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp; 70000 | 70000 |
| **Total Short-Term Securities — 7.3%** <br>**(Cost: $416,418)** | **Total Short-Term Securities — 7.3%** <br>**(Cost: $416,418)** | 416465 |
| **Total Investments — 105.6%** <br>**(Cost: $5,332,860)** | **Total Investments — 105.6%** <br>**(Cost: $5,332,860)** | 6016431 |
| **Liabilities in Excess of Other Assets — (5.6)%** | **Liabilities in Excess of Other Assets — (5.6)%** | (317304)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | $5699127 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. 

<sup>(c)</sup> All or a portion of this security is on loan.

<sup>(d)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(e)</sup> Affiliate of the Fund.

<sup>(f)</sup> Annualized 7-day yield as of period end.

<sup>(g)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2025 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*07/31/25*<br>| &nbsp;&nbsp; *Proceeds* <br>*from Sales*<br>| *Net Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*10/31/25*<br>| *Shares* <br>*Held at* <br>*10/31/25*<br>| *Income* | &nbsp;&nbsp; *Capital* <br>*Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| BlackRock Cash Funds: Institutional, SL Agency Shares | $183837<br> $162588 <br><sup>(a)</sup><br>| $— | $26 | $14 | $346465 | 346292 | $288 <br><sup>(b)</sup><br>| $— |
| BlackRock Cash Funds: Treasury, SL Agency Shares | &nbsp;&nbsp;&nbsp; 50000<br> 20000 <br><sup>(a)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp; 70000 | 70000 | &nbsp;&nbsp;&nbsp;&nbsp; 817 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |
|  |  |  | $26 | $14 | $416465 |  | $1105 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

**Fair Value Hierarchy as of Period End** 

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges that the Fund has the ability to access for identical assets or liabilities;

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

------

Schedule of Investments (unaudited)(continued)

October 31, 2025

**iShares Health Innovation Active ETF**

**Fair Value Hierarchy as of Period End (continued)**

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks | &nbsp;&nbsp; $4724166 | &nbsp;&nbsp; $786249 | &nbsp;&nbsp; $960 | &nbsp;&nbsp; $5511375 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Stocks | &nbsp;&nbsp; — | &nbsp;&nbsp; 88591 | &nbsp;&nbsp; — | &nbsp;&nbsp; 88591 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 416465 | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 416465 |
|  | &nbsp;&nbsp; $5140631 | &nbsp;&nbsp; $874840 | &nbsp;&nbsp; $960 | &nbsp;&nbsp; $6016431 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation** | **Portfolio Abbreviation** |
| ADR | American Depositary Receipt |
| NVS | Non-Voting Shares |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** BlackRock ETF Trust

- **b. Investment Company Act file number:** 811-23402

- **c. CIK number of Registrant:** 0001761055

- **d. LEI of Registrant:** 5493007WBHAKV9JVS642

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 BELLEVUE PARKWAY

  - **City:** WILMINGTON

  - **State:** DE

  - **Foreign country:** US

  - **Zip / Postal Code:** 19809

  - **Telephone number:** 800-441-7762

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares Health Innovation Active ETF

- **b. EDGAR series identifier (if any):** S000069260

- **c. LEI of Series:** 549300QSHQQEGUGOU050

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2025-10-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $6405372.36

**Total Liabilities:** $706233.92

**Net Assets:** $5699138.44

**Cash Not Reported:** $1962.12

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000221226 | 5.64%                | 2.56%                | 6.30%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $4634.69                 | $219122.79                                 |
| Month 2  | $4720.99                 | $101691.32                                 |
| Month 3  | $-19176.57               | $319189.79                                 |

**Designated Index Information**

- **Index Name:** STOXX GLOBAL BREAKTHROUGH HEALTHCARE

- **Index Identifier:** STFSHIUN

### Schedule of Portfolio Investments

| Name                                           | Title                                                 | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Abbott Laboratories                            | Abbott Laboratories                                   | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |      1516 | NS      | $187407.92    | 3.29%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                                     | AbbVie Inc                                            | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |       443 | NS      | $96591.72     | 1.69%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA ABIOMED INC                             | CONTRA ABIOMED INC                                    | CUSIP: 003CVR016<br>LEI: N/A                  | Long             |  | CORP              | US        |       246 | NS      | $568.26       | 0.01%             |  |  |  | No            |                  3 | On Loan: No      |
| Agilent Technologies Inc                       | Agilent Technologies Inc                              | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |       841 | NS      | $123088.76    | 2.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Allogene Therapeutics Inc                      | Allogene Therapeutics Inc                             | CUSIP: 019770106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1965 | NS      | $2436.60      | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                    | Alnylam Pharmaceuticals Inc                           | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |       115 | NS      | $52444.60     | 0.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora Inc                                    | Cencora Inc                                           | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |       157 | NS      | $53036.17     | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                      | Amgen Inc                                             | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |       305 | NS      | $91021.15     | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc                        | Apogee Therapeutics Inc                               | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       155 | NS      | $8771.45      | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                                    | Arcellx Inc                                           | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       351 | NS      | $31677.75     | 0.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc                          | Arcus Biosciences Inc                                 | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       915 | NS      | $18043.80     | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Arvinas Inc                                    | Arvinas Inc                                           | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       650 | NS      | $6591.00      | 0.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                            | Ascendis Pharma A/S                                   | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |        58 | NS      | $11692.80     | 0.21%             |  |  |  | No            |                  1 | On Loan: —       |
| AstraZeneca PLC                                | AstraZeneca PLC                                       | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |       325 | NS      | $26780.00     | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Autolus Therapeutics PLC                       | Autolus Therapeutics PLC                              | CUSIP: 05280R100<br>LEI: 549300C0KZP8EYROLL02 | Long             | EC               | CORP              | GB        |      2035 | NS      | $3154.25      | 0.06%             |  |  |  | No            |                  1 | On Loan: —       |
| Avalo Therapeutics Inc                         | Avalo Therapeutics Inc                                | CUSIP: 05338F306<br>LEI: 549300GPK6FPJ3X8SZ39 | Long             | EC               | CORP              | US        |       170 | NS      | $3065.10      | 0.05%             |  |  |  | No            |                  1 | On Loan: —       |
| Avidity Biosciences Inc                        | Avidity Biosciences Inc                               | CUSIP: 05370A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |        87 | NS      | $6076.95      | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc                        | Axsome Therapeutics Inc                               | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |       281 | NS      | $37932.19     | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Beam Therapeutics Inc                          | Beam Therapeutics Inc                                 | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       507 | NS      | $12680.07     | 0.22%             |  |  |  | No            |                  1 | On Loan: —       |
| BeOne Medicines Ltd                            | BeOne Medicines Ltd                                   | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |       101 | NS      | $31358.48     | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Bicycle Therapeutics PLC                       | Bicycle Therapeutics PLC                              | CUSIP: 088786108<br>LEI: 213800XKUI6R7GKC3E43 | Long             | EC               | CORP              | GB        |       245 | NS      | $1977.15      | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Rad Laboratories Inc                       | Bio-Rad Laboratories Inc                              | CUSIP: 090572207<br>LEI: 549300ZC1GPV35XYDK53 | Long             | EC               | CORP              | US        |       156 | NS      | $49849.80     | 0.87%             |  |  |  | No            |                  1 | On Loan: No      |
| BioMarin Pharmaceutical Inc                    | BioMarin Pharmaceutical Inc                           | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |       212 | NS      | $11356.84     | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                     | Biogen Inc                                            | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |       775 | NS      | $119559.25    | 2.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                                | Bio-Techne Corp                                       | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |      1142 | NS      | $71454.94     | 1.25%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                    | BioNTech SE                                           | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |        77 | NS      | $8001.07      | 0.14%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA BLUEPRINT MEDIC                         | CONTRA BLUEPRINT MEDIC                                | CUSIP: 096CVR048<br>LEI: 5299004CC60O9T5HVM83 | Long             |  | CORP              | US        |       110 | NS      | $106.70       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Boston Scientific Corp                         | Boston Scientific Corp                                | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |       907 | NS      | $91353.04     | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc                           | Bridgebio Pharma Inc                                  | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |       920 | NS      | $57628.80     | 1.01%             |  |  |  | No            |                  1 | On Loan: —       |
| Bristol-Myers Squibb Co                        | Bristol-Myers Squibb Co                               | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |      1713 | NS      | $78917.91     | 1.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Bruker Corp                                    | Bruker Corp                                           | CUSIP: 116794108<br>LEI: LEBZ6VLQ6I8XB1NHVY15 | Long             | EC               | CORP              | US        |       437 | NS      | $17016.78     | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Charles River Laboratories International Inc   | Charles River Laboratories International Inc          | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |       412 | NS      | $74188.84     | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc                               | Cytokinetics Inc                                      | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |       140 | NS      | $8902.60      | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                   | Danaher Corp                                          | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |       406 | NS      | $87444.28     | 1.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Denali Therapeutics Inc                        | Denali Therapeutics Inc                               | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |       910 | NS      | $14814.80     | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                     | Dexcom Inc                                            | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |       973 | NS      | $56648.06     | 0.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Disc Medicine Inc                              | Disc Medicine Inc                                     | CUSIP: 254604101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       131 | NS      | $11294.82     | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc                          | Dyne Therapeutics Inc                                 | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       550 | NS      | $12419.00     | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Edgewise Therapeutics Inc                      | Edgewise Therapeutics Inc                             | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       586 | NS      | $10712.08     | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp                      | Edwards Lifesciences Corp                             | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |      1880 | NS      | $155006.00    | 2.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Elanco Animal Health Inc                       | Elanco Animal Health Inc                              | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |      1425 | NS      | $31563.75     | 0.55%             |  |  |  | No            |                  1 | On Loan: —       |
| Enanta Pharmaceuticals Inc                     | Enanta Pharmaceuticals Inc                            | CUSIP: 29251M106<br>LEI: 529900SSN4DODDQSN594 | Long             | EC               | CORP              | US        |       445 | NS      | $4877.20      | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Exact Sciences Corp                            | Exact Sciences Corp                                   | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |      1786 | NS      | $115536.34    | 2.03%             |  |  |  | No            |                  1 | On Loan: —       |
| Exelixis Inc                                   | Exelixis Inc                                          | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |      1426 | NS      | $55143.42     | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| EyePoint Pharmaceuticals Inc                   | EyePoint Pharmaceuticals Inc                          | CUSIP: 30233G209<br>LEI: 549300QE1RU34T50MR69 | Long             | EC               | CORP              | US        |       475 | NS      | $6217.75      | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| 4D Molecular Therapeutics Inc                  | 4D Molecular Therapeutics Inc                         | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       295 | NS      | $3392.50      | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA FREQUENCY THERA                         | CONTRA FREQUENCY THERA                                | CUSIP: 358CVR025<br>LEI: N/A                  | Long             |  | CORP              | US        |       420 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Gilead Sciences Inc                            | Gilead Sciences Inc                                   | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |       766 | NS      | $91759.14     | 1.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                            | Guardant Health Inc                                   | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |      1495 | NS      | $139064.90    | 2.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics Inc                      | Halozyme Therapeutics Inc                             | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |       425 | NS      | $27705.75     | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Harmony Biosciences Holdings Inc               | Harmony Biosciences Holdings Inc                      | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       362 | NS      | $10342.34     | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| HeartFlow Inc                                  | HeartFlow Inc                                         | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |        21 | NS      | $780.36       | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Hologic Inc                                    | Hologic Inc                                           | CUSIP: 436440101<br>LEI: 549300DYP6F5ZJL0LB74 | Long             | EC               | CORP              | US        |       922 | NS      | $68145.02     | 1.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                                   | Illumina Inc                                          | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |       787 | NS      | $97225.98     | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                    | Incyte Corp                                           | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |       212 | NS      | $19817.76     | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                     | Insmed Inc                                            | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |       555 | NS      | $105228.00    | 1.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Inspire Medical Systems Inc                    | Inspire Medical Systems Inc                           | CUSIP: 457730109<br>LEI: 549300XQQCQ7HCJKTW25 | Long             | EC               | CORP              | US        |        66 | NS      | $4757.28      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp                                   | Insulet Corp                                          | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |       407 | NS      | $127395.07    | 2.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                                     | Genmab A/S                                            | CUSIP: 000000000<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |       363 | NS      | $103537.69    | 1.82%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical Inc                         | Intuitive Surgical Inc                                | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |       162 | NS      | $86553.36     | 1.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc                      | Ionis Pharmaceuticals Inc                             | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |      1007 | NS      | $74820.10     | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                             | IQVIA Holdings Inc                                    | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |       600 | NS      | $129876.00    | 2.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                              | Johnson & Johnson                                     | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |       976 | NS      | $184337.12    | 3.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Kodiak Sciences Inc                            | Kodiak Sciences Inc                                   | CUSIP: 50015M109<br>LEI: 254900IXI5NI8C9OQE24 | Long             | EC               | CORP              | US        |       150 | NS      | $2718.75      | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| LB Pharmaceuticals Inc                         | LB Pharmaceuticals Inc                                | CUSIP: 50180M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1113 | NS      | $17952.69     | 0.32%             |  |  |  | No            |                  1 | On Loan: —       |
| Lantheus Holdings Inc                          | Lantheus Holdings Inc                                 | CUSIP: 516544103<br>LEI: 5299005HUB5IOJGO7S39 | Long             | EC               | CORP              | US        |       306 | NS      | $17653.14     | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| MBX Biosciences Inc                            | MBX Biosciences Inc                                   | CUSIP: 55287L101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       870 | NS      | $19105.20     | 0.34%             |  |  |  | No            |                  1 | On Loan: —       |
| UCB SA                                         | UCB SA                                                | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |       420 | NS      | $107999.62    | 1.90%             |  |  |  | No            |                  2 | On Loan: No      |
| McKesson Corp                                  | McKesson Corp                                         | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |        66 | NS      | $53548.44     | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Sartorius AG                                   | Sartorius AG                                          | CUSIP: 000000000<br>LEI: 529900EQV2DY4FOAMU38 | Long             | EP               | CORP              | DE        |       322 | NS      | $88591.21     | 1.55%             |  |  |  | No            |                  2 | On Loan: No      |
| Merck & Co Inc                                 | Merck & Co Inc                                        | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |       600 | NS      | $51588.00     | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA MIRATI THERAPEU                         | CONTRA MIRATI THERAPEU                                | CUSIP: 604CVR027<br>LEI: 529900GYRW59IDQV6N54 | Long             |  | CORP              | US        |       334 | NS      | $260.52       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Moderna Inc                                    | Moderna Inc                                           | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |      2686 | NS      | $72951.76     | 1.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Eisai Co Ltd                                   | Eisai Co Ltd                                          | CUSIP: 000000000<br>LEI: 353800HDEE0ZYEX4QV91 | Long             | EC               | CORP              | JP        |      2100 | NS      | $62371.22     | 1.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Natera Inc                                     | Natera Inc                                            | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       560 | NS      | $111400.80    | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                     | Neurocrine Biosciences Inc                            | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |       631 | NS      | $90365.51     | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                                   | Nuvalent Inc                                          | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       351 | NS      | $34861.32     | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvation Bio Inc                               | Nuvation Bio Inc                                      | CUSIP: 67080N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1918 | NS      | $10011.96     | 0.18%             |  |  |  | No            |                  1 | On Loan: —       |
| Ocular Therapeutix Inc                         | Ocular Therapeutix Inc                                | CUSIP: 67576A100<br>LEI: 529900ABAWFXOHSIHG03 | Long             | EC               | CORP              | US        |       485 | NS      | $5655.10      | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Olema Pharmaceuticals Inc                      | Olema Pharmaceuticals Inc                             | CUSIP: 68062P106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       306 | NS      | $2744.82      | 0.05%             |  |  |  | No            |                  1 | On Loan: —       |
| ORIC Pharmaceuticals Inc                       | ORIC Pharmaceuticals Inc                              | CUSIP: 68622P109<br>LEI: 54930033FJRNEYBW0L25 | Long             | EC               | CORP              | US        |       652 | NS      | $8580.32      | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Oruka Therapeutics Inc                         | Oruka Therapeutics Inc                                | CUSIP: 687604108<br>LEI: 529900TG7O4ESUDMGI54 | Long             | EC               | CORP              | US        |       315 | NS      | $8873.55      | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc                           | PTC Therapeutics Inc                                  | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |       435 | NS      | $29714.85     | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Penumbra Inc                                   | Penumbra Inc                                          | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |       130 | NS      | $29558.10     | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                                    | Novartis AG                                           | CUSIP: 000000000<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |       425 | NS      | $52598.71     | 0.92%             |  |  |  | No            |                  2 | On Loan: No      |
| Roche Holding AG                               | Roche Holding AG                                      | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |       297 | NS      | $96204.29     | 1.69%             |  |  |  | No            |                  2 | On Loan: No      |
| Sonova Holding AG                              | Sonova Holding AG                                     | CUSIP: 000000000<br>LEI: 5299004A0QNX7FBNHS61 | Long             | EC               | CORP              | CH        |       105 | NS      | $28640.87     | 0.50%             |  |  |  | No            |                  2 | On Loan: No      |
| Pfizer Inc                                     | Pfizer Inc                                            | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |      2192 | NS      | $54032.80     | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| EssilorLuxottica SA                            | EssilorLuxottica SA                                   | CUSIP: 000000000<br>LEI: 549300M3VH1A3ER1TB49 | Long             | EC               | CORP              | FR        |        85 | NS      | $31128.58     | 0.55%             |  |  |  | No            |                  2 | On Loan: No      |
| Lonza Group AG                                 | Lonza Group AG                                        | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |       220 | NS      | $151916.93    | 2.67%             |  |  |  | No            |                  2 | On Loan: No      |
| Protagonist Therapeutics Inc                   | Protagonist Therapeutics Inc                          | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       466 | NS      | $36636.92     | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENXBIO Inc                                  | REGENXBIO Inc                                         | CUSIP: 75901B107<br>LEI: 549300EOES47LATSET33 | Long             | EC               | CORP              | US        |       510 | NS      | $6512.70      | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp                                  | Repligen Corp                                         | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |       650 | NS      | $96889.00     | 1.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                       | Revolution Medicines Inc                              | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |       317 | NS      | $18652.28     | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                     | Rhythm Pharmaceuticals Inc                            | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |       864 | NS      | $98288.64     | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp                      | Scholar Rock Holding Corp                             | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |       210 | NS      | $6220.20      | 0.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Stoke Therapeutics Inc                         | Stoke Therapeutics Inc                                | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |      1242 | NS      | $37309.68     | 0.65%             |  |  |  | No            |                  1 | On Loan: —       |
| Stryker Corp                                   | Stryker Corp                                          | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |       107 | NS      | $38117.68     | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc                        | Summit Therapeutics Inc                               | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       250 | NS      | $4727.50      | 0.08%             |  |  |  | No            |                  1 | On Loan: —       |
| Tempus AI Inc                                  | Tempus AI Inc                                         | CUSIP: 88023B103<br>LEI: 2549009LA0KWRAGQBX50 | Long             | EC               | CORP              | US        |       525 | NS      | $47171.25     | 0.83%             |  |  |  | No            |                  1 | On Loan: —       |
| Teva Pharmaceutical Industries Ltd             | Teva Pharmaceutical Industries Ltd                    | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |      1437 | NS      | $29429.76     | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc                   | Thermo Fisher Scientific Inc                          | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |       208 | NS      | $118017.12    | 2.07%             |  |  |  | No            |                  1 | On Loan: No      |
| TScan Therapeutics Inc                         | TScan Therapeutics Inc                                | CUSIP: 89854M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2792 | NS      | $5416.48      | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| United Therapeutics Corp                       | United Therapeutics Corp                              | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |        16 | NS      | $7126.88      | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Upstream Bio Inc                               | Upstream Bio Inc                                      | CUSIP: 91678A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       293 | NS      | $7574.05      | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Ventyx Biosciences Inc                         | Ventyx Biosciences Inc                                | CUSIP: 92332V107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1445 | NS      | $12325.85     | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc                        | Viking Therapeutics Inc                               | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |       116 | NS      | $4417.28      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA VIGIL NEUROSCIE                         | CONTRA VIGIL NEUROSCIE                                | CUSIP: 926CVR010<br>LEI: N/A                  | Long             |  | CORP              | US        |       484 | NS      | $24.20        | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Vir Biotechnology Inc                          | Vir Biotechnology Inc                                 | CUSIP: 92764N102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       566 | NS      | $3373.36      | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Vor BioPharma Inc                              | Vor BioPharma Inc                                     | CUSIP: 929033207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       305 | NS      | $7353.55      | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Voyager Therapeutics Inc                       | Voyager Therapeutics Inc                              | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |       975 | NS      | $4553.25      | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| West Pharmaceutical Services Inc               | West Pharmaceutical Services Inc                      | CUSIP: 955306105<br>LEI: 5493007NKRGM1RJQ1P16 | Long             | EC               | CORP              | US        |       226 | NS      | $63747.82     | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |
| BlackRock Funds III                            | BlackRock Cash Funds: Institutional, SL Agency Shares | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |    350574 | NS      | $350749.18    | 6.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Wuxi Biologics Cayman Inc                      | Wuxi Biologics Cayman Inc                             | CUSIP: 000000000<br>LEI: 5493001TD2TH6VDTJU11 | Long             | EC               | CORP              | KY        |      7500 | NS      | $34980.70     | 0.61%             |  |  |  | No            |                  2 | On Loan: No      |
| BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES | BlackRock Cash Funds: Treasury, SL Agency Shares      | CUSIP: 066922477<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |     70000 | NS      | $70000.00     | 1.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Samsung Biologics Co Ltd                       | Samsung Biologics Co Ltd                              | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | KR        |        31 | NS      | $26503.24     | 0.47%             |  |  |  | No            |                  2 | On Loan: No      |
| Galderma Group AG                              | Galderma Group AG                                     | CUSIP: 000000000<br>LEI: 89450001OK6O8ELQ4584 | Long             | EC               | CORP              | CH        |       198 | NS      | $36770.97     | 0.65%             |  |  |  | No            |                  2 | On Loan: No      |
| Daiichi Sankyo Co Ltd                          | Daiichi Sankyo Co Ltd                                 | CUSIP: 000000000<br>LEI: 353800XGIU2IHQGC9504 | Long             | EC               | CORP              | JP        |       600 | NS      | $14332.87     | 0.25%             |  |  |  | No            |                  2 | On Loan: No      |
| Zealand Pharma A/S                             | Zealand Pharma A/S                                    | CUSIP: 000000000<br>LEI: 549300ITBB1ULBL4CZ12 | Long             | EC               | CORP              | DK        |       312 | NS      | $24702.46     | 0.43%             |  |  |  | No            |                  2 | On Loan: No      |
| Nyxoah SA                                      | Nyxoah SA                                             | CUSIP: 000000000<br>LEI: 5493002O1ESKZ18OXR80 | Long             | EC               | CORP              | BE        |       757 | NS      | $3928.83      | 0.07%             |  |  |  | No            |                  1 | On Loan: —       |
| Akeso Inc                                      | Akeso Inc                                             | CUSIP: 000000000<br>LEI: 254900ECWYGR3QW5GF30 | Long             | EC               | CORP              | KY        |      1000 | NS      | $14560.89     | 0.26%             |  |  |  | No            |                  2 | On Loan: No      |
| Alkermes PLC                                   | Alkermes PLC                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | IE        |       870 | NS      | $26709.00     | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                                   | Biohaven Ltd                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | VG        |       206 | NS      | $3543.20      | 0.06%             |  |  |  | No            |                  1 | On Loan: —       |
| ICON PLC                                       | ICON PLC                                              | CUSIP: 000000000<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | IE        |       112 | NS      | $19243.84     | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Kiniksa Pharmaceuticals International Plc      | Kiniksa Pharmaceuticals International Plc             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        |       431 | NS      | $15951.31     | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Medtronic PLC                                  | Medtronic PLC                                         | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |      1995 | NS      | $180946.50    | 3.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Novocure Ltd                                   | Novocure Ltd                                          | CUSIP: 000000000<br>LEI: 213800YPP55UMHWA4826 | Long             | EC               | CORP              | JE        |      1340 | NS      | $17165.40     | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Merus NV                                       | Merus NV                                              | CUSIP: 000000000<br>LEI: 549300W8GPUWU8QNU293 | Long             | EC               | CORP              | NL        |       266 | NS      | $25232.76     | 0.44%             |  |  |  | No            |                  1 | On Loan: —       |
| QIAGEN NV                                      | QIAGEN NV                                             | CUSIP: 000000000<br>LEI: 54930036WK3GMCN17Z57 | Long             | EC               | CORP              | NL        |      1102 | NS      | $51628.70     | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| WaVe Life Sciences Ltd                         | WaVe Life Sciences Ltd                                | CUSIP: 000000000<br>LEI: 54930070006GPKFYZ813 | Long             | EC               | CORP              | SG        |       466 | NS      | $4212.64      | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-11-28

**Name of Applicant:** BlackRock ETF Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer